PMDA
- Application: Shingrix
- Local brand name: Shingrix
- Status: approved
🇯🇵 recombinant subunit Herpes zoster vaccine in Japan
recombinant subunit Herpes zoster vaccine (recombinant subunit Herpes zoster vaccine) regulatory status in Japan.
Marketing authorisation
recombinant subunit Herpes zoster vaccine in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology / Infectious Disease approved in Japan
Frequently asked questions
Is recombinant subunit Herpes zoster vaccine approved in Japan?
Yes. PMDA has authorised it.
Who is the marketing authorisation holder for recombinant subunit Herpes zoster vaccine in Japan?
University Health Network, Toronto is the originator. The local marketing authorisation holder may differ — check the official source linked above.